162 related articles for article (PubMed ID: 36676710)
21. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
Haruyama Y; Kataoka H
World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
[TBL] [Abstract][Full Text] [Related]
22. Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy.
Chen IP; Ariizumi S; Nakano M; Yamamoto M
J Gastroenterol; 2014 Jan; 49(1):117-25. PubMed ID: 23532638
[TBL] [Abstract][Full Text] [Related]
23. Concomitant use of heat-shock protein 70, glutamine synthetase and glypican-3 is useful in diagnosis of HBV-related hepatocellular carcinoma with higher specificity and sensitivity.
Moudi B; Heidari Z; Mahmoudzadeh-Sagheb H; Alavian SM; Lankarani KB; Farrokh P; Randel Nyengaard J
Eur J Histochem; 2018 Jan; 62(1):2859. PubMed ID: 29569872
[TBL] [Abstract][Full Text] [Related]
24. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis.
Taniguchi M; Mizuno S; Yoshikawa T; Fujinami N; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Gotohda N; Nakatsura T
Cancer Sci; 2020 Aug; 111(8):2747-2759. PubMed ID: 32449239
[TBL] [Abstract][Full Text] [Related]
25. Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma.
Ofuji K; Saito K; Suzuki S; Shimomura M; Shirakawa H; Nobuoka D; Sawada Y; Yoshimura M; Tsuchiya N; Takahashi M; Yoshikawa T; Tada Y; Konishi M; Takahashi S; Gotohda N; Nakamoto Y; Nakatsura T
Oncotarget; 2017 Jun; 8(23):37835-37844. PubMed ID: 28035063
[TBL] [Abstract][Full Text] [Related]
26. GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma.
Ning J; Jiang S; Li X; Wang Y; Deng X; Zhang Z; He L; Wang D; Jiang Y
BMC Pulm Med; 2021 Jun; 21(1):199. PubMed ID: 34112123
[TBL] [Abstract][Full Text] [Related]
27. [Clinicopathological characteristics and prognosis analysis with Paget's disease of the breast].
Wang J; Yu WJ; Wang X; Wang X; Tian YT
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):523-527. PubMed ID: 30060361
[No Abstract] [Full Text] [Related]
28. Frequent expression of glypican-3 in Merkel cell carcinoma: an immunohistochemical study of 55 cases.
He H; Fang W; Liu X; Weiss LM; Chu PG
Appl Immunohistochem Mol Morphol; 2009 Jan; 17(1):40-6. PubMed ID: 18813128
[TBL] [Abstract][Full Text] [Related]
29. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
Zhou F; Shang W; Yu X; Tian J
Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
[TBL] [Abstract][Full Text] [Related]
30. Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma.
Shimizu Y; Mizuno S; Fujinami N; Suzuki T; Saito K; Konishi M; Takahashi S; Gotohda N; Tada T; Toyoda H; Kumada T; Miura M; Suto K; Yamaji T; Matsuda T; Endo I; Nakatsura T
Cancer Sci; 2020 Feb; 111(2):334-342. PubMed ID: 31774932
[TBL] [Abstract][Full Text] [Related]
31. Identification of biomarkers for hepatocellular carcinoma by semiquantitative immunocytochemistry.
Mu H; Lin KX; Zhao H; Xing S; Li C; Liu F; Lu HZ; Zhang Z; Sun YL; Yan XY; Cai JQ; Zhao XH
World J Gastroenterol; 2014 May; 20(19):5826-38. PubMed ID: 24914343
[TBL] [Abstract][Full Text] [Related]
32. Biological and clinical significance of the glypican-3 gene in human lung adenocarcinoma: An in silico analysis.
Imon RR; Aktar S; Morshed N; Nur SM; Mahtarin R; Rahman FA; Talukder MEK; Alam R; Karpiński TM; Ahammad F; Zamzami MA; Tan SC
Medicine (Baltimore); 2023 Nov; 102(45):e35347. PubMed ID: 37960765
[TBL] [Abstract][Full Text] [Related]
33. Identification of Glypican-3 as a potential metastasis suppressor gene in gastric cancer.
Han S; Ma X; Zhao Y; Zhao H; Batista A; Zhou S; Zhou X; Yang Y; Wang T; Bi J; Xia Z; Bai Z; Garkavtsev I; Zhang Z
Oncotarget; 2016 Jul; 7(28):44406-44416. PubMed ID: 27259271
[TBL] [Abstract][Full Text] [Related]
34. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
Esheba GE; Pate LL; Longacre TA
Am J Surg Pathol; 2008 Apr; 32(4):600-7. PubMed ID: 18277882
[TBL] [Abstract][Full Text] [Related]
35. Assessment of proliferating activity in Paget's disease of the nipple by double stain immunohistochemistry.
Buxant F; Fayt I; Noel JC
Eur J Gynaecol Oncol; 2009; 30(5):500-2. PubMed ID: 19899400
[TBL] [Abstract][Full Text] [Related]
36. The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression.
Xue R; Feng J; Meng Q; Lv F; Zhu Y; Yu H; Zhang S; Song C; Sun L; Yue Z; Feng S; Che R; Xiang Q; Jing X
J Gastroenterol Hepatol; 2017 Aug; 32(8):1503-1511. PubMed ID: 28087980
[TBL] [Abstract][Full Text] [Related]
37. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
Zhu XT; Yuan JH; Zhu TT; Li YY; Cheng XY
FEBS J; 2016 Oct; 283(20):3739-3754. PubMed ID: 27573079
[TBL] [Abstract][Full Text] [Related]
38. Morphological evidence for field effect as a mechanism for tumour spread in mammary Paget's disease.
Mai KT
Histopathology; 1999 Dec; 35(6):567-76. PubMed ID: 10583581
[TBL] [Abstract][Full Text] [Related]
39. Glypican 3 overexpression in primary and metastatic Wilms tumors.
Tretiakova M; Zynger DL; Luan C; Andeen NK; Finn LS; Kocherginsky M; Teh BT; Yang XJ
Virchows Arch; 2015 Jan; 466(1):67-76. PubMed ID: 25366870
[TBL] [Abstract][Full Text] [Related]
40. Diffuse and canalicular patterns of glypican-3 expression reflect malignancy of hepatocellular carcinoma.
Kawaida M; Yamazaki K; Tsujikawa H; Fukuma M; Abe Y; Kitago M; Shinoda M; Kitagawa Y; Sakamoto M
Pathol Int; 2019 Mar; 69(3):125-134. PubMed ID: 30729617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
